Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
1	19/YH/0188	264996	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.	16/12/2019	14/01/2020	07/08/2019	15/01/2020	15/01/2020	15/01/2020	11/02/2020	Please select	
2	19/NE/0312	266862	AN OPEN LABEL PHASE 1A/B STUDY OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS (TIMEPOINT)	24/09/2019	15/01/2020	13/11/2019	15/01/2020	29/01/2020	29/01/2020	11/02/2020	Please select	
3	19/LO/1336	256748	An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years	15/05/2019	15/01/2020	13/11/2019	20/01/2020	23/01/2020	24/01/2020		Sponsor	Sponsor has had difficulty getting their database ready to recruit and randomise. The research team are still waiting for the green light.
4	19/ES/0112	268502	Personalised Nutrition in Non-Alcoholic Fatty Liver Disease: Feasibility of a Nutrigenomic Therapeutic Approach	09/07/2019	02/01/2020	10/10/2019	13/01/2020	13/01/2020	13/01/2020	11/02/2020	Please select	
5	19/SC/0311	262176	ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis	21/08/2019	16/01/2020	07/08/2019	17/01/2020	23/01/2020	27/01/2020		Sponsor	Study has just reopened after being suspended by sponsor due to COVID-19
6	18/LO/1937	249639	A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors	30/01/2020	10/02/2020	01/03/2019	12/02/2020	24/02/2020	24/02/2020	01/07/2020	Neither	This is a very rare patient group, they need to have a rare condition and then they have to fail standard therapy
7	17/EE/0368	213669	STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)	28/01/2019	13/02/2020	10/11/2017	11/02/2020	13/02/2020	13/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
8	19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	28/02/2019	09/01/2020	17/12/2019	23/01/2020	06/02/2020	06/02/2020	10/03/2020	Please select	
9	18/NW/0110	236974	NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadjuvant therapy in ER-positive intermediate recurrence score primary breast cancer	03/10/2019	20/01/2020	12/06/2019	13/02/2020	21/02/2020	21/02/2020		Sponsor	Study was suspended by sponsor due to COVID-19 and has recently re-opened and actively looking for patients
10	19/NE/0317	265622	High Flow Weaning in Preterm Infants: Physiology and Outcomes	20/01/2020	05/02/2020	07/01/2020	06/02/2020	06/02/2020	06/02/2020		Sponsor	Study was suspended by sponsor due to COVID-19 and has recently re-opened and is actively looking for patients

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
11	18/NE/0264	250542	Topical rVA576 for treatment of atopic keratoconjunctivitis: a randomised placebo single masked parallel trial (TRACKER)	11/07/2019	21/01/2020	27/09/2018	03/01/2020	10/02/2020	10/02/2020		Sponsor	Study was initally suspended by sponsor due to COVID-19 then closed at Newcastle
12	19/LO/1270	261294	CRAFT: Cerclarge after full dilatation caesarean section; an investigation into the role of previous in labour caesarean section in future preterm birth risk and potential management strategies	16/08/2019	07/02/2020	20/09/2019	17/06/2019	21/02/2020	21/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
13	19/YH/0229	266822	A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)	31/01/2020	21/02/2020	07/09/2019	21/02/2020	25/02/2020	25/02/2020		Sponsor	Study suspended by sponsor due to COVID-19
14	18/EE/0282	249797	AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	23/10/2019	14/01/2020	29/10/2018	16/01/2020	05/02/2020	05/02/2020	27/02/2020	Please select	
15	18/SC/0286	246516	A Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 after a Single Oral Dose and Multiple Ascending Oral Doses in Healthy Subjects and Patients with Primary Mitochondrial Disease	01/11/2019	13/02/2020	24/10/2019	14/02/2020	21/02/2020	21/02/2020	23/09/2020	Sponsor	Study was initially suspended by sponsor due to COVID-19
16	19/LO/1116	258919	A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies	14/02/2020	24/02/2020	24/09/2019	25/02/2020	25/02/2020	25/02/2020	03/08/2020	Sponsor	Study was suspended by sponsor due to COVID-19

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
17	19/NW/0317	262846	A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough	19/02/2020	19/02/2020	12/07/2019	21/02/2020	25/02/2020	25/02/2020		Sponsor	Study initally suspended by sponsor due to COVID-19. Team now actively looking for recruits
18	17/NW/0581	214739	Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial	28/11/2019	25/02/2020	07/08/2018	27/02/2020	03/03/2020	06/03/2020		Sponsor	Study suspended by sponsor due to COVID-19
19	19/NW/0504	264255	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy	05/02/2020	21/02/2020	09/12/2019	05/03/2020	12/03/2020	12/03/2020	07/07/2020	Sponsor	Study was suspended by sponsor due to COVID-19
20	19/EM/0189	264788	A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	05/12/2019	14/02/2020	17/07/2017	14/02/2020	09/03/2020	09/03/2020		Sponsor	Study suspended by sponsor due to COVID-19
21	19/LO/0333	259569	A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus (CMV) seropositive recipients (R+) of an allogenic hematopoietic stem cell transplant (HSCT)	05/08/2019	10/02/2020	02/05/2019	02/03/2020	05/03/2020	05/03/2020	17/08/2020	Neither	No patients were seen initially due to COVID-19
22	19/NE/0269	268944	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)	27/08/2019	05/02/2020	31/10/2019	25/02/2020	28/02/2020	05/03/2020	06/07/2020	Sponsor	Study was suspended initially by sponsor due to COVID-19
23	19/EM/0264	266058	In younger adults with unstable ankle fractures treated with close contact casting, is ankle function not worse than those treated with surgical intervention? The Fractured Ankle Management Evaluation (FAME) Trial.	17/02/2020	25/02/2020	03/09/2019	26/02/2020	06/03/2020	10/03/2020		Sponsor	Study suspended by sponsor due to COVID-19
24	19/NE/0328	270912	M19-164: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to risankizumab.	24/10/2019	07/02/2020	19/11/2019	06/03/2020	06/03/2020	06/03/2020		Neither	No patients seen due to COVID-29

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
25	19/LO/1423	269751	A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS AND YOUNG ADULTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION OR RECURRENT/REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS	24/02/2020	11/03/2020	21/11/2019	06/03/2020	13/03/2020	13/03/2020		Sponsor	Study suspended by sponsor initially due to COVID-19. No eligible patients seen during Q3
26	19/WA/0263	266172	Treatment of Hidradenitis Suppurativa Evaluation Study	21/11/2019	07/02/2020	03/10/2019	26/02/2020	03/03/2020	06/03/2020	10/09/2020	Sponsor	Study was suspended initially by sponsor due to COVID-19
27	19/EM/0300	267054	Effectiveness of an image analysing algorithm to diagnose non-melanoma skin cancers compared to gold standard histological determination.	13/01/2020	07/02/2020	17/10/2019	10/03/2020	10/03/2020	13/03/2020	28/09/2020	Sponsor	Study suspended intially by sponsor due to COVID-19
28	20/SC/0154	281800	A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults	30/03/2020	30/03/2020	26/03/2020	30/03/2020	30/03/2020	30/03/2020	31/03/2020	Please select	
29	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	13/03/2020	13/03/2020	17/03/2020	13/03/2020	25/03/2020	25/03/2020	26/03/2020	Please select	
30	18/SW/0047	232201	Distal pancreatectomy, minimally invasive or open, for malignancy (DIPLOMA) A pan-European, randomised controlled, multicentre, patient blinded, non-inferiority trial.	21/11/2018	15/01/2020	15/08/2019	16/01/2020	16/01/2020	16/01/2020		Sponsor	Problems with the Green Light from Sponsor caused original delays to recruitment then the site had COVID-19 delays
31	19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects	25/03/2020	08/04/2020	17/01/2020	08/04/2020	14/04/2020	14/04/2020	18/06/2020	Sponsor	Initials delays with recruitment were caused by sponsor suspending study due to COVID-19
32	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	06/04/2020	07/04/2020	23/07/2018	08/04/2020	14/04/2020	14/04/2020	20/04/2020	Please select	
33	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	23/04/2020	23/04/2020	03/04/2020	23/04/2020	23/04/2020	23/04/2020	29/09/2020	Neither	No patient presented due to the strict criteria eligibility
34	20/SC/0179	281904	A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19	07/05/2020	20/05/2020	04/05/2020	21/05/2020	21/05/2020	21/05/2020	26/05/2020	Please select	
35	20/LO/0279	277975	ReCerf® total hip resurfacing	11/06/2020	11/06/2020	22/04/2020	18/06/2020	22/06/2020	22/06/2020	30/06/2020	Please select	
36	20/SC/0201	282769	ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients	28/05/2020	03/06/2020	28/04/2020	05/06/2020	08/06/2020	08/06/2020	18/06/2020	Please select	
37	20/HRA/2191	283184	Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial”	10/06/2020	16/06/2020	06/05/2020	18/06/2020	23/06/2020	23/06/2020	24/11/2020	Neither	No patients presented initially due to the strict criteria eligibility

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
38	19/NE/0130	237080	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Paediatric and Young Adult Patients with Relapsed or Refractory Malignancies	24/02/2020	10/03/2020	23/07/2019	14/07/2020	14/07/2020	14/07/2020	06/08/2020	Sponsor	Set up was delayed due to COVID-19
39	18/LO/0508	241903	An Open-Label, Multicentre, Long-Term Follow-Up Study to Investigate the Safety and Durability of Response Following Dosing of a Novel Adeno-Associated Viral Vector (FLT180a) in Patients With Haemophilia B	19/02/2020	08/07/2020	15/05/2018	09/07/2020	09/07/2020	09/07/2020	13/07/2020	Please select	
40	20/EE/0135	282213	Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)	22/06/2020	16/07/2020	06/05/2020	17/07/2020	17/07/2020	20/07/2020	01/10/2020	Neither	No patients presented due to the strict criteria eligibility initially
41	20/YH/0090	278137	AN OPEN-LABEL,MULTICENTER, ROLLOVER STUDYTO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OFGANTENERUMABIN PARTICIPANTSWITHALZHEIMER'S DISEASE	27/05/2020	12/08/2020	20/04/2020	14/08/2020	14/08/2020	17/08/2020	04/11/2020	Neither	This study deals with a rare disease no patient presented to the team until Q3
42	19/ES/0126	271121	A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations	03/10/2019	02/03/2020	01/11/2019	05/08/2020	25/08/2020	25/08/2020	28/08/2020	Sponsor	Initial delays with set up were due to COVID-19
43	19/LO/1837	271981	An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M1774 in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors	30/03/2020	16/06/2020	14/01/2020	23/07/2020	12/08/2020	12/08/2020	06/10/2020	Neither	Initial delays with set up were due to COVID-19. No eligible patient initially were seen once the study was approved. This study deals with a rare disease
44	19/LO/1753	269460	A phase 2, ranodmised, double-blind, placebo controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 for subutaneous injection administered every week in patients with Alport Syndrome	29/06/2020	21/07/2020	13/02/2020	20/07/2020	03/08/2020	03/08/2020	20/08/2020	Please select	
45	17/NW/0649	227917	The ASsessment and Physiotherapy managEment of ataxia in Children following surgical resection of posterior fossa Tumour	11/07/2019	10/03/2020	05/03/2018	04/02/2020	12/08/2020	13/08/2020		Neither	Initial delays were due to COVID-19. Since the study was approved no patients have been identified that are suitable for the study
46	19/NW/0342	264974	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation	17/02/2020	09/03/2020	25/07/2019	16/03/2020	12/08/2020	12/08/2020	08/10/2020	Sponsor	Initial delays were caused by COVID-19. Since approval limited amount of patients have fitted the strict eligibility criteria
47	17/WA/0155	223941	Primary care Management of lower Urinary tract Symptoms in men: Development and validation of a diagnostic and decision-making aid.	21/01/2020	09/09/2020	23/08/2017	29/09/2020	29/09/2020	29/09/2020	10/12/2020	Neither	The team screened patients at the weekly clinic and intially no eligible patients were found until December

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
48	19/LO/1195	261755	A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment	17/08/2020	15/09/2020	05/12/2019	21/09/2020	28/09/2020	28/09/2020	04/11/2020	Please select	
49	19/NE/0215	234453	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	03/10/2019	19/02/2020	07/11/2019	09/07/2020	09/09/2020	30/09/2020		Sponsor	Set up was delayed due to COVID-19 and no patients have been seen who fits the strict eligibility criteria
50	20/NE/0058	275056	A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)	23/07/2020	21/08/2020	30/04/2020	03/09/2020	14/09/2020	15/09/2020	15/12/2020	Neither	Due to the nature of the disease criteria. This study focuses on relapsed osteosarcoma and we did not have any relapsed patients until December
51	19/NE/0357	271261	A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMOR Study	29/11/2019	30/07/2020	06/01/2020	31/08/2020	01/09/2020	01/09/2020		Sponsor	Because of the pandemic, the sponsor put on hold recruitment whilst they revised their protocol.
52	19/NI/0126	254829	SMALL: A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision	09/03/2020	14/09/2020	15/10/2019	17/09/2020	18/09/2020	25/09/2020		Neither	Delays with recruitment were due to the pandemic
53	19/LO/1949	274671	AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA	06/08/2020	06/08/2020	17/02/2020	10/09/2020	14/09/2020	15/09/2020	28/09/2020	Please select	
54	19/SC/0107	237804	A phase II trial assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer	04/08/2020	04/08/2020	05/07/2019	18/09/2020	21/09/2020	21/09/2020	15/10/2020	Sponsor	Initial delays were due to contracting delays within the sponsor company

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
55	20/YH/0174	283089	A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.	11/06/2020	29/07/2020	20/05/2020	01/09/2020	02/09/2020	02/09/2020	03/11/2020	Neither	No patients seen initially due to COVID-19 and the strict eligibility criteria
56	19/LO/0062	255909	A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients	11/12/2019	24/09/2020	03/04/2019	13/10/2020	15/10/2020	15/10/2020		Neither	No patient were identified initially however, two patients are identified and awaiting to achieve stable background treatment to make them eligible for the protocol. This strategy has been communicated and agreed with Sponsor
57	19/LO/0063	255904	A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION	11/02/2019	24/09/2020	04/04/2019	13/10/2020	15/10/2020	15/10/2020		Neither	This study is a sub study and as there are no patients in the main study ADVANCE 301 and we are unable to recruit however, two patients identified are awaiting to achieve stable background treatment to make them eligible for the protocol. This strategy has been communicated and agreed with Sponsor
58	19/NW/0046	227794	A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma	11/05/2020	25/09/2020	26/03/2019	29/09/2020	01/10/2020	13/10/2020		Neither	This study deals with rare patients and none have been identified that meet the strict eligibility based on their liver function
59	19/YH/0222	252494	Positional Therapy for Obstructive Sleep Apnoea: a Randomised Controlled Trial to assess the effect on Health and Wellbeing in Older and Younger People.	05/03/2020	12/08/2020	24/07/2019	13/10/2020	13/10/2020	14/10/2020	25/11/2020	Neither	Initial set up was suspended due to COVID-19
60	18/YH/0358	242342	A randomised controlled trial to establish the clinical and cost effectiveness of expectant management versus pre-operative imaging with Magnetic Resonance Cholangiopancreatography (MRCP) in patients with symptomatic gallstones undergoing laparoscopic cholecystectomy at low or moderate risk of common bile duct stones	02/03/2020	02/10/2020	12/12/2018	02/10/2020	02/10/2020	06/10/2020	26/11/2020	Please select	
61	19/NE/0361	272352	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjogren's Syndrome (SS)	21/07/2020	21/07/2020	15/01/2020	20/08/2020	15/10/2020	15/10/2020		Sponsor	Initial set up was suspended due to COVID-19. A contract amendment is still going through to change elements of the protocol causing delays to patient recruitment
62	20/EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	21/01/2020	03/08/2020	03/04/2020	16/10/2020	20/10/2020	20/10/2020	31/12/2020	Sponsor	Initial delays were caused by contracting delays with the sponsor then greenlight was not given until November. Study opened to recruitment early December 2020
63	19/SW/0191	270987	Ross for Valve replacement in Adults(REVIVAL) Registry	11/05/2020	11/05/2020	30/01/2020	17/07/2020	20/10/2020	20/10/2020		Neither	Initial set up was suspended due to COVID-19. No patients were seen due to the elective lists being cancelled initially due to COVID-19
64	19/LO/1664	261665	Patient Reported Outcomes in patients with Persistent Rheumatoid Arthritis (PROsPer-RA)	18/03/2020	21/08/2020	26/11/2019	28/10/2020	29/10/2020	30/10/2020		Neither	Initial set up was suspended due to COVID-19 and site opening was hugely delayed

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
65	20/NE/0052	277285	Elite Study	17/09/2020	21/10/2020	15/04/2020	27/10/2020	27/10/2020	29/10/2020	08/12/2020	Please select	
66	19/NE/0263	261557	Open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD patients who have been previously treated in one of the GIVINOSTAT studies.	27/02/2020	14/09/2020	04/03/2020	20/10/2020	21/10/2020	21/10/2020	11/11/2020	Please select	
67	20/NE/0189	280542	Feasibility study for identification of patients at potential risk of silent aspiration in an acute stroke setting: a comparison of clinical swallow examination and cough reflex testing	05/03/2020	30/10/2020	17/09/2020	30/10/2020	30/10/2020	30/10/2020	05/11/2020	Please select	
68	20/LO/0828	279777	Master protocol of two randomized, double-blind, placebo controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in patients naïve to omalizumab and in patients who are intolerant or incomplete responders to omalizumab	04/08/2020	29/09/2020	09/07/2020	14/10/2020	16/10/2020	16/10/2020		Neither	The study nationally is struggling to recruit its first patient, due to a 4 month washout period and short recruitment period. However, this has now been extended and we hope to have the first patient soon. Patient population for this condition and relevant inclusion/exclusion criteria is small
69	20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	28/09/2020	28/09/2020	29/07/2020	13/10/2020	16/10/2020	16/10/2020	26/11/2020	Please select	
70	20/YH/0231	284781	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	02/10/2020	20/10/2020	10/09/2020	20/10/2020	20/10/2020	21/10/2020	29/10/2020	Please select	
71	19/EE/0362	272768	A Randomised Multiple Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically Ill Children (Oxy-PICU)	15/10/2020	15/10/2020	23/12/2019	20/10/2020	21/10/2020	21/10/2020	29/10/2020	Please select	
72	20/HRA/4788	288786	A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19	12/10/2020	19/10/2020	05/10/2020	20/10/2020	20/10/2020	20/10/2020	29/10/2020	Please select	
73	19/LO/1652	271917	Phase 3, open-label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)	29/10/2020	30/10/2020	28/01/2020	09/11/2020	09/11/2020	10/11/2020		Please select	
74	20/SC/0027	271232	A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101	30/03/2020	13/10/2020	06/04/2020	11/11/2020	17/11/2020	17/11/2020		Sponsor	Delays to recruitment have been caused by the sponsor confirming the finer details of an amendment

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
75	20/NW/0310	267092	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).	14/11/2019	12/10/2020	24/09/2020	04/11/2020	04/11/2020	04/11/2020	04/12/2020	Please select	
76	10/H0803/121	53663	Genetic Linkage Evaluation in Inherited C ardiac Conditions	30/06/2020	09/07/2020	08/01/2020	19/11/2020	20/11/2020	20/11/2020		Neither	Initial set up was suspended due to COVID-19. No patients have been identified due the strict inclusion criteria
77	19/LO/0213	256261	A Phase 1 Trial of the combination of PS101-Mediated Acoustic Cluster Therapy (ACT) with Chemotherapy for the Treatment of Liver Metastasis in Patients with Solid Tumours with an Expansion Cohort in Metastatic Colorectal and Pancreatic Cancer	16/10/2020	20/10/2020	07/05/2019	22/10/2020	22/10/2020	03/11/2020		Neither	This study is not formally open yet at our site, as COVID has delayed Marsden NHS finishing the first bit
78	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	17/09/2020	18/11/2020	10/11/2020	19/11/2020	20/11/2020	20/11/2020	01/12/2020	Please select	
79	19/NE/0310	263546	A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation	26/10/2020	26/10/2020	31/03/2020	18/12/2020	30/12/2020	30/12/2020		Both	Intial delays were caused by contacting problems within the NHS and Sponsor provider
80	19/LO/1926	274398	A Phase 1/2 Open Label Study to Assess the Safety and Efficacy of UCB6114 Administered Intravenously to Participants with Advanced Solid Tumors	11/02/2020	17/11/2020	19/02/2020	08/12/2020	09/12/2020	09/12/2020		Please select	
81	20/LO/0731	279972	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis	13/05/2020	25/11/2020	25/06/2020	16/12/2020	16/12/2020	17/12/2020		NHS Provider	Delays to recruitment has been caused by the loss of a research nurse and the study needs two. A nurse has been employed and will start with the study team in the near future
82	20/SC/0031	275229	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis	27/11/2020	27/11/2020	26/06/2020	16/12/2020	17/12/2020	17/12/2020		NHS Provider	Staff capacity issues caused delays in receiving the sponsor's green light to commence recruitment
83	20/EE/0118	283014	COG-UK HOCI study	09/09/2020	07/12/2020	15/06/2020	07/12/2020	07/12/2020	07/12/2020	15/12/2020	Please select	
84	20/EM/0142	282923	Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)	15/09/2020	25/11/2020	16/07/2020	10/12/2020	14/12/2020	14/12/2020		Please select	
85	18/WM/0207	239150	TWIST – Trial of Wound drain In Surgical site infection in kidney Transplant	15/10/2020	15/10/2020	15/11/2018	24/11/2020	01/12/2020	01/12/2020		Sponsor	Contracting delays within sponsor company

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
86	20/WM/0054	264593	CRAFFT – Children's Radius - Acute Fracture Fixation Trial: A multi-centre prospective randomised non-inferiority trial of surgical reduction versus non-surgical casting for displaced distal radius fractures in children.	16/10/2020	16/12/2020	16/04/2020	18/12/2020	18/12/2020	18/12/2020		Please select	
87	19/SW/0166	268532	Ross for Valve replacement in Adults(REVIVAL) trial	04/11/2019	17/02/2020	01/11/2019	14/10/2020	20/10/2020	20/10/2020		Neither	Initial set up was suspended due to COVID-19 then due to the pandemic elective surgeries were postponed, so the team were unable to consent
88	20/NE/0032	273692	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER	07/09/2020	01/10/2020	28/07/2020	09/10/2020	09/10/2020	09/10/2020		Neither	A change in population due to COVID 19 (patients presenting with more advanced disease and poorer performance status) have caused delays to recruitment
89	20/LO/0453	1003010	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA	15/09/2020	15/09/2020	29/04/2020	27/10/2020	28/10/2020	28/10/2020		NHS Provider	Contracting delays within the Trust. Recruitment delays have been caused by the loss of a research nurse and the study needs two. A research nurse has been employed and will start with the study team in the near future